BioVie Inc. has successfully enrolled 60 patients in its Phase 2 SUNRISE-PD study evaluating bezisterim for early Parkinson’s disease. All participants were diagnosed within the past four years and remain levodopa-naïve. This enrollment milestone positions the company to report top-line safety and efficacy data later this year, a key inflection point that could validate bezisterim’s potential to slow disease progression and inform discussions with regulatory authorities.

BioVie shares fell by 4.7% during Wednesday’s trading session, with daily volume of approximately 79,600 shares representing a 35% decline from the 122,000-share average. The stock’s consensus analyst rating stands at Moderate Buy, reflecting one Strong Buy and one Sell recommendation. Recent research notes include an upgrade from sell to hold by Wall Street Zen and a reaffirmation of a sell (e+) rating by Weiss Ratings. The company’s market capitalization is approximately $9.1 million, and its trailing twelve-month price-to-earnings ratio remains negative at -0.17.

Several institutional investors have added to or initiated stakes in BioVie during the third quarter. Prelude Capital Management and Prosperity Wealth Management each established new positions valued at roughly $275,000, while Citadel Advisors allocated approximately $199,000 to the company. Smaller purchases were made by Jane Street Group and XTX Topco, contributing to a total institutional ownership of 4.59%. These investments reflect growing interest in BioVie’s pipeline despite recent volatility.

In its latest quarterly report, BioVie posted an EPS loss of $0.98, missing analyst expectations by $0.19. The company continues to invest heavily in clinical programs for hepatic encephalopathy and Parkinson’s disease, driving cash burn. With development milestones on the horizon and no revenue generation to date, BioVie’s capital runway and future financing strategies will be critical factors for investors monitoring the stock.